Foresee Pharmaceuticals, announced that the company has been selected for a late-breaking oral presentation on the positive primary outcomes of its aderamastat Phase 2 proof-of-concept allergic asthma study at the European Respiratory Society International Congress 2023 taking place in Milan, Italy from September 9-13, 2023.
